257 related articles for article (PubMed ID: 8545243)
61. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist.
Xu JY; Seyed-Mozaffari A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1996 Nov; 279(2):539-47. PubMed ID: 8930155
[TBL] [Abstract][Full Text] [Related]
62. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
[TBL] [Abstract][Full Text] [Related]
63. Intrathecal cholecystokinin octapeptide attenuates the antinociception and release of immunoreactive Met-enkephalin induced by intraventricular beta-endorphin in the rat.
Suh HH; Collins KA; Tseng LF
Neuropeptides; 1992 Mar; 21(3):131-7. PubMed ID: 1321361
[TBL] [Abstract][Full Text] [Related]
64. Involvement of epsilon and kappa opioid receptors in inhibition of the tail-flick response induced by bremazocine in the mouse.
Tseng LF; Collins KA
J Pharmacol Exp Ther; 1991 Oct; 259(1):330-6. PubMed ID: 1656027
[TBL] [Abstract][Full Text] [Related]
65. Differential cross-tolerance between analgesia produced by alpha 2-adrenoceptor agonists and receptor subtype selective opioid treatments.
Paul D; Tran JG
Eur J Pharmacol; 1995 Jan; 272(1):111-4. PubMed ID: 7713142
[TBL] [Abstract][Full Text] [Related]
66. The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine.
Randich A; Robertson JD; Willingham T
Brain Res; 1993 Feb; 603(2):186-200. PubMed ID: 8096421
[TBL] [Abstract][Full Text] [Related]
67. Effects of intrathecal or intracerebroventricular pretreatment with pertussis toxin on antinociception induced by beta-endorphin or morphine administered intracerebroventricularly in mice.
Chung KM; Song DK; Suh HW; Lee MH; Kim YH
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jun; 349(6):588-93. PubMed ID: 7969510
[TBL] [Abstract][Full Text] [Related]
68. ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,488H in the tail flick test in mice.
Lutfy K; Doan P; Nugyen M; Weber E
Pharmacol Res; 1998 Dec; 38(6):453-60. PubMed ID: 9990654
[TBL] [Abstract][Full Text] [Related]
69. Visceral antinociceptive effects of spinal clonidine combined with morphine, [D-Pen2, D-Pen5] enkephalin, or U50,488H.
Harada Y; Nishioka K; Kitahata LM; Kishikawa K; Collins JG
Anesthesiology; 1995 Aug; 83(2):344-52. PubMed ID: 7631957
[TBL] [Abstract][Full Text] [Related]
70. Pentobarbital antagonism of morphine analgesia mediated by spinal cholecystokinin.
Rady JJ; Lin W; Fujimoto JM
J Pharmacol Exp Ther; 1998 Mar; 284(3):878-85. PubMed ID: 9495845
[TBL] [Abstract][Full Text] [Related]
71. Chronic administration of cholecystokinin antagonists reverses the enhancement of spinal morphine analgesia induced by acute pretreatment.
Kellstein DE; Mayer DJ
Brain Res; 1990 May; 516(2):263-70. PubMed ID: 2364292
[TBL] [Abstract][Full Text] [Related]
72. Differential effects of mu-, delta- and kappa-opioid receptor agonists on the discriminative stimulus properties of cocaine in rats.
Suzuki T; Mori T; Tsuji M; Maeda J; Kishimoto Y; Misawa M; Nagase H
Eur J Pharmacol; 1997 Apr; 324(1):21-9. PubMed ID: 9137909
[TBL] [Abstract][Full Text] [Related]
73. Delta opioid antagonist, 16-Me cyprenorphine, selectively attenuates conditional fear- and DPDPE-induced analgesia on the formalin test.
Fanselow MS; Calcagnetti DJ; Helmstetter FJ
Pharmacol Biochem Behav; 1989 Feb; 32(2):469-73. PubMed ID: 2542994
[TBL] [Abstract][Full Text] [Related]
74. Role of central mu, delta-1, and kappa-1 opioid receptors in opioid-induced muscle rigidity in the rat.
Vankova ME; Weinger MB; Chen DY; Bronson JB; Motis V; Koob GF
Anesthesiology; 1996 Sep; 85(3):574-83. PubMed ID: 8853088
[TBL] [Abstract][Full Text] [Related]
75. Nitric oxide/cyclic guanosine monophosphate system in the spinal cord differentially modulates intracerebroventricularly administered morphine- and beta-endorphin-induced antinociception in the mouse.
Xu JY; Tseng LF
J Pharmacol Exp Ther; 1995 Jul; 274(1):8-16. PubMed ID: 7616452
[TBL] [Abstract][Full Text] [Related]
76. Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice.
Narita M; Takahashi Y; Takamori K; Funada M; Suzuki T; Misawa M; Nagase H
Jpn J Pharmacol; 1993 May; 62(1):15-24. PubMed ID: 8393497
[TBL] [Abstract][Full Text] [Related]
77. Antisense oligodeoxynucleotide to a delta-opioid receptor messenger RNA selectively blocks the antinociception induced by intracerebroventricularly administered delta-, but not mu-, epsilon- or kappa-opioid receptor agonists in the mouse.
Wang HQ; Kampine JP; Tseng LF
Neuroscience; 1996 Nov; 75(2):445-52. PubMed ID: 8931008
[TBL] [Abstract][Full Text] [Related]
78. Effects of ibogaine on the development of tolerance to antinociceptive action of mu-, delta- and kappa-opioid receptor agonists in mice.
Cao YJ; Bhargava HN
Brain Res; 1997 Mar; 752(1-2):250-4. PubMed ID: 9106464
[TBL] [Abstract][Full Text] [Related]
79. Intrathecal administration of thiorphan, bestatin, desipramine and fluoxetine differentially potentiate the antinociceptive effects induced by beta-endorphin and morphine, administered intracerebroventricularly.
Suh HH; Tseng LL
Neuropharmacology; 1990 Mar; 29(3):207-14. PubMed ID: 2139187
[TBL] [Abstract][Full Text] [Related]
80. Effects of ginsenosides injected intrathecally or intracerebroventricularly on antinociception induced by morphine administrated intracerebroventricularly in the mouse.
Suh HW; Song DK; Kim YH
Gen Pharmacol; 1997 Nov; 29(5):873-7. PubMed ID: 9347341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
